AI Neurotechnology for Aging Societies -- Task-load and Dementia EEG Digital Biomarker Development Using Information Geometry Machine Learning Methods
This work addresses the medical and economic burden of dementia in aging societies by aiming to improve early screening and monitoring, though it appears incremental as it builds on existing EEG and machine learning methods.
The paper tackles the problem of early dementia detection by developing EEG-based digital biomarkers using information geometry machine learning to classify task-load responses, achieving preliminary results in discriminating low versus high task-load auditory or tactile stimuli with variability similar to dementia.
Dementia and especially Alzheimer's disease (AD) are the most common causes of cognitive decline in elderly people. A spread of the above mentioned mental health problems in aging societies is causing a significant medical and economic burden in many countries around the world. According to a recent World Health Organization (WHO) report, it is approximated that currently, worldwide, about 47 million people live with a dementia spectrum of neurocognitive disorders. This number is expected to triple by 2050, which calls for possible application of AI-based technologies to support an early screening for preventive interventions and a subsequent mental wellbeing monitoring as well as maintenance with so-called digital-pharma or beyond a pill therapeutical approaches. This paper discusses our attempt and preliminary results of brainwave (EEG) techniques to develop digital biomarkers for dementia progress detection and monitoring. We present an information geometry-based classification approach for automatic EEG-derived event related responses (ERPs) discrimination of low versus high task-load auditory or tactile stimuli recognition, of which amplitude and latency variabilities are similar to those in dementia. The discussed approach is a step forward to develop AI, and especially machine learning (ML) approaches, for the subsequent application to mild-cognitive impairment (MCI) and AD diagnostics.